No business profile yet.
Size PureTech Health (PRTC.L) is a United Kingdom Health Care company (Biotechnology) with a market value of $378M, the 324th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £117.40 on 18 Nov 2026.
Performance Over six months the shares fell 14.7%, against -31.1% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue fell 4.1% over the last twelve months (peer median +6.3%); the operating margin is -1,616.9% (peer median 5.0%).
Valuation It trades at 27.4× enterprise value to sales against a peer median of 3.9× (2nd most expensive of 16).
Capital Return on invested capital runs 57.1 points below its cost of capital (12.2% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £4.74M | £3.54M | £3.78M | £2.68M | £12.7M |
| Revenue growth | — | -6% | +41% | -79% | — |
| Gross profit | £2.28M | £994,772 | £983,713 | -£1.29M | n/a |
| EBITDA | -£74.2M | -£72.2M | -£104M | -£114M | -£153M |
| Net income | £1.35M | -£83.3M | £41.9M | -£52.9M | -£40.9M |
| Free cash flow | -£61.2M | -£64.6M | -£105M | -£85.3M | -£147M |
| Capital expenditure | £4,481 | £4,553 | £8,608 | £197,096 | £1.77M |
| Total debt | n/a | £14.7M | £18.0M | £20.0M | £61.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRTC.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.2% | -9.2% | 3rd highest of 20 |
| 6-month return | -14.7% | -31.1% | 4th highest of 20 |
| Distance from 52-week high | -18.2% | -47.2% | 2nd highest of 20 |
| Revenue growth (TTM) | -4.1% | +6.3% | 4th lowest of 16 |
| Operating margin | -1,616.9% | 5.0% | 2nd lowest of 16 |
| EV / Sales | 27.4× | 3.9× | 2nd most expensive of 16 |
| ROIC minus cost of capital | -57.1 pp | -8.4 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | 1.5× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | 10.3× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |